LAB Q3 2025 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena

LABStandard BioTools Inc.

$388M

Q3 2025 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$20M-56.5% YoY

Gross Profit

$9M48.5% margin

Operating Income

-$23M-120.0% margin

Net Income

-$35M-177.4% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

-10.2%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$23M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$540M

Total Liabilities

$140M

Stockholders' Equity

$400M

Cash & Equivalents

$129M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$45M	-56.5%
Gross Profit	$9M	$23M	-59.2%
Operating Income	-$23M	-$32M	+26.0%
Net Income	-$35M	-$27M	-28.8%

Revenue Segments

Product

$14M41%

Consumables

$9M26%

Service and Other Revenue

$6M17%

Instruments

$5M15%

Geographic Segments

Americas

$8M40%

EMEA

$7M37%

Asia Pacific

$4M23%